While glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide and tirzepatide (a dual GIP/GLP-1 agonist) have revolutionized care, the pipeline is advancing toward novel mechanisms offering potential for enhanced efficacy, tolerability, and convenience
In human CaMKK2, Ca 2+ -calmodulin binding induces autophosphorylation of a threonine residue (Thr85) located in the N-terminal regulatory sequence, which creates a molecular memory that enables CaMKK2 to remain in the activated state following an initial, transient Ca 2+ -signal [33]
Understanding your genetic predisposition helps your provider select not just the delivery form, but the starting dose and escalation timeline most likely to work for your biology
Across the studies that were included, over 32,000 subjects received GLP-1 agonists and over 27,000 received placebo